Dartmouth Events

Description
The presentation will:
1. Review the biology of myelodysplastic syndrome and its relationship to acute leukemias and non-neoplastic clonal myeloid proliferations.
2. Explore the influence of mutated TP53 on the clinical behavior of myelodysplastic syndrome and acute myeloid leukemia.
3. Explain how incorporating genetic information into the diagnosis of myeloid neoplasms can inform patient management.   

Bio
Dr Robert Hasserjian is Professor of Pathology at Harvard Medical School and a Hematopathologist at Massachusetts General Hospital, where he is Director of the Hematopathology Fellowship Program.  His research interests are in the discovery of pathologic and genetic features that uderlie the biology of myeloid and lymphoid neoplasms, particularly myelodysplastic syndromes and acute myeloid leukemia. He the current President of the Society for Hematopathology and was one of the pathology leaders of the 2022 International Consensus Classification of Myeloid Neoplasms.
 
"Dartmouth Health is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.”    

 “Dartmouth Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.”

Robert P. Hasserjian, MD reports that he is a consultant/advisor for Bluebird Bio, Daiichi-Sankyo, and Jazz Pharmaceuticals.  All of the relevant financial relationships listed for this individual have been mitigated.